Cover Image
市場調查報告書

類鐸受體8:開發中產品分析

Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 366668
出版日期 內容資訊 英文 74 Pages
訂單完成後即時交付
價格
Back to Top
類鐸受體8:開發中產品分析 Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2016
出版日期: 2016年07月13日 內容資訊: 英文 74 Pages
簡介

本報告提供以類鐸受體8為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

類鐸受體8 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • 3M Drug Delivery Systems
  • Foamix Pharmaceuticals Ltd.
  • Folia Biotech Inc.
  • Galderma S.A.
  • Idera Pharmaceuticals, Inc.
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Resolve Therapeutics, LLC
  • VentiRx Pharmaceuticals, Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0390TDB

Summary

Global Markets Direct's, 'Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2016', provides in depth analysis on Toll Like Receptor 8 (CD288 or TLR8) targeted pipeline therapeutics.

The report provides comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 8 (CD288 or TLR8)
  • The report reviews Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Toll Like Receptor 8 (CD288 or TLR8)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Toll Like Receptor 8 (CD288 or TLR8) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Toll Like Receptor 8 (CD288 or TLR8) Overview
  • Therapeutics Development
    • Toll Like Receptor 8 (CD288 or TLR8) - Products under Development by Stage of Development
    • Toll Like Receptor 8 (CD288 or TLR8) - Products under Development by Therapy Area
    • Toll Like Receptor 8 (CD288 or TLR8) - Products under Development by Indication
  • Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Toll Like Receptor 8 (CD288 or TLR8) - Products under Development by Companies
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Toll Like Receptor 8 (CD288 or TLR8) - Companies Involved in Therapeutics Development
    • 3M Drug Delivery Systems
    • Foamix Pharmaceuticals Ltd.
    • Folia Biotech Inc.
    • Galderma S.A.
    • Idera Pharmaceuticals, Inc.
    • MedImmune, LLC
    • Merck & Co., Inc.
    • Resolve Therapeutics, LLC
    • VentiRx Pharmaceuticals, Inc.
  • Toll Like Receptor 8 (CD288 or TLR8) - Drug Profiles
    • 854-A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug 1 to Agonize TLR7 and TLR8 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug 2 to Agonize TLR7 and TLR8 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Agonize TLR7 and TLR8 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • imiquimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMO-8400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMO-9200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JB-6121 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • leishmaniasis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-9197 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • motolimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • resiquimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RSLV-132 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize TLR7/8/9 for Cancer, Alzheimer's Disease and Infectious Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VTX-1463 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VTX-294 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Toll Like Receptor 8 (CD288 or TLR8) - Dormant Projects
  • Toll Like Receptor 8 (CD288 or TLR8) - Discontinued Products
  • Toll Like Receptor 8 (CD288 or TLR8) - Featured News & Press Releases
    • May 26, 2016: Resolve To Present Data On Lupus Studies At International Rheumatology Conference
    • Feb 10, 2016: Resolve Announces Positive Clinical Data From RSLV-132 Lupus Study
    • Dec 05, 2015: Idera Pharmaceuticals Reports Positive Data From Ongoing Phase 1/2 Clinical Trial of IMO-8400 in Patients With Waldenstrom's Macroglobulinemia
    • Nov 09, 2015: Idera Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of IMO-8400 in Patients with Dermatomyositis
    • Nov 05, 2015: Idera Pharmaceuticals to Present Phase 1/2 IMO-8400 Clinical Data in Waldenstrom's Macroglobulinemia at the 2015 American Society of Hematology Annual Meeting
    • May 18, 2015: Idera Pharmaceuticals Provides Development Update on IMO-9200, an Antagonist of Toll-like Receptors
    • Apr 27, 2015: VentiRx Pharmaceuticals Granted Orphan Drug Designation in the European Union For Motolimod in the Treatment of Ovarian Cancer
    • Apr 01, 2015: Idera Announces FDA Orphan Drug Designation for IMO-8400 for the Treatment of Diffuse Large B-Cell Lymphoma
    • Dec 30, 2014: Idera Provides Key Updates on Clinical Development of IMO-8400 for Treatment of Waldenstrom's Macroglobulinemia
    • Dec 08, 2014: Idera Pharmaceuticals Presents Data Supporting IMO-8400 as Novel Therapy for Genetically Defined Forms of B-Cell Lymphoma at Annual ASH Meeting
    • Nov 06, 2014: Idera Pharmaceuticals Announces Upcoming Presentations of Data on IMO-8400 From Oncology Programs at Key Scientific Meetings
    • Oct 14, 2014: Idera Pharmaceuticals Expands Pipeline by Initiating Clinical Development of Proprietary TLR Antagonist Candidate IMO-9200
    • Sep 03, 2014: Ludwig Cancer Research And Cancer Research Institute Collaborate On Evaluation Of Ventirx's Investigational Immunotherapy
    • Sep 02, 2014: VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer
    • Aug 08, 2014: Idera Pharmaceuticals and The Myositis Association Join Forces to Advance the Clinical Development of a Novel TLR Antagonist, IMO-8400, for the Treatment of Myositis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by 3M Drug Delivery Systems, H2 2016
  • Pipeline by Foamix Pharmaceuticals Ltd., H2 2016
  • Pipeline by Folia Biotech Inc., H2 2016
  • Pipeline by Galderma S.A., H2 2016
  • Pipeline by Idera Pharmaceuticals, Inc., H2 2016
  • Pipeline by MedImmune, LLC, H2 2016
  • Pipeline by Merck & Co., Inc., H2 2016
  • Pipeline by Resolve Therapeutics, LLC, H2 2016
  • Pipeline by VentiRx Pharmaceuticals, Inc., H2 2016
  • Dormant Projects, H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top